Pasithea Therapeutics (KTTA) announced the appointment of Dr. James Lee to its scientific advisory board, SAB, to help guide development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease, IBD, ulcerative colitis, Crohn’s disease, primary sclerosing cholangitis and ankylosing spondylitis.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KTTA:
- Pasithea Therapeutics presents updated interim data from Phase 1 PAS-004 study
- Pasithea Therapeutics announces preclinical data on PAS-004
- Pasithea Therapeutics announces initiation of Phase 1/1b study of PAS-004
- 3 Penny Stocks to Watch Now, 5/8/25
- Pasithea Therapeutics Raises $6.3 Million in Stock Offering